S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
Critical asset just had biggest fall on record (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Critical asset just had biggest fall on record (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
Critical asset just had biggest fall on record (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Critical asset just had biggest fall on record (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
Critical asset just had biggest fall on record (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Critical asset just had biggest fall on record (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
Critical asset just had biggest fall on record (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Critical asset just had biggest fall on record (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?

Ultragenyx Pharmaceutical (RARE) News Today

$52.75
-0.91 (-1.70%)
(As of 02/28/2024 ET)
SourceHeadline
MarketBeat logoCantor Fitzgerald Reiterates "Overweight" Rating for Ultragenyx Pharmaceutical (NASDAQ:RARE)
americanbankingnews.com - February 28 at 4:56 AM
MarketBeat logoJPMorgan Chase & Co. Raises Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $88.00
americanbankingnews.com - February 28 at 4:56 AM
globenewswire.com logoUltragenyx to Participate at Investor Conferences in March
globenewswire.com - February 27 at 4:30 PM
marketbeat.com logoAvidity Partners Management LP Decreases Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
marketbeat.com - February 27 at 4:25 PM
marketbeat.com logoUltragenyx Pharmaceutical's (RARE) Overweight Rating Reiterated at Cantor Fitzgerald
marketbeat.com - February 27 at 10:25 AM
marketbeat.com logoUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Holdings Lowered by Connor Clark & Lunn Investment Management Ltd.
marketbeat.com - February 26 at 8:18 AM
globenewswire.com logoUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com - February 23 at 4:05 PM
marketbeat.com logoClearbridge Investments LLC Sells 469,676 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
marketbeat.com - February 23 at 7:52 AM
MarketBeat logoCantor Fitzgerald Analysts Cut Earnings Estimates for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
americanbankingnews.com - February 23 at 2:20 AM
marketbeat.com logoCantor Fitzgerald Comments on Ultragenyx Pharmaceutical Inc.'s FY2024 Earnings (NASDAQ:RARE)
marketbeat.com - February 22 at 7:35 AM
MarketBeat logoUltragenyx Pharmaceutical (NASDAQ:RARE) Price Target Raised to $111.00 at Canaccord Genuity Group
americanbankingnews.com - February 22 at 4:18 AM
marketbeat.com logoRafferty Asset Management LLC Purchases 21,376 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
marketbeat.com - February 19 at 7:15 AM
MarketBeat logoUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Consensus Rating of "Moderate Buy" from Brokerages
americanbankingnews.com - February 19 at 3:26 AM
marketbeat.com logoUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Rating of "Moderate Buy" by Analysts
marketbeat.com - February 19 at 3:25 AM
finanznachrichten.de logoUltragenyx Pharmaceutical Inc.: Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
finanznachrichten.de - February 18 at 1:31 PM
marketbeat.com logoDeutsche Bank AG Buys 60,001 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
marketbeat.com - February 18 at 6:25 AM
finance.yahoo.com logoUltragenyx Pharmaceutical Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line
finance.yahoo.com - February 17 at 9:28 AM
marketbeat.com logoState of New Jersey Common Pension Fund D Buys 18,045 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
marketbeat.com - February 17 at 6:46 AM
marketbeat.com logoUltragenyx Pharmaceutical (NASDAQ:RARE) Issues Earnings Results
marketbeat.com - February 16 at 2:35 PM
marketbeat.com logoUltragenyx Pharmaceutical (NASDAQ:RARE) Trading 6.4% Higher After Earnings Beat
marketbeat.com - February 16 at 2:33 PM
markets.businessinsider.com logoBarclays Keeps Their Buy Rating on Ultragenyx Pharmaceutical (RARE)
markets.businessinsider.com - February 16 at 2:29 PM
markets.businessinsider.com logoAnalysts Conflicted on These Healthcare Names: Ultragenyx Pharmaceutical (RARE), Nurix Therapeutics (NRIX) and AMN Healthcare Services (AMN)
markets.businessinsider.com - February 16 at 2:29 PM
finance.yahoo.com logoQ4 2023 Ultragenyx Pharmaceutical Inc Earnings Call
finance.yahoo.com - February 16 at 2:29 PM
finance.yahoo.com logoUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2023 Earnings Call Transcript
finance.yahoo.com - February 16 at 2:29 PM
finance.yahoo.com logoUltragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat
finance.yahoo.com - February 16 at 9:29 AM
marketbeat.com logoUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Sold by New York State Common Retirement Fund
marketbeat.com - February 16 at 4:32 AM
markets.businessinsider.com logoAnalysts Conflicted on These Healthcare Names: CSL (OtherCMXHF), Pro Medicus Limited (OtherPMCUF) and Ultragenyx Pharmaceutical (RARE)
markets.businessinsider.com - February 15 at 11:09 PM
benzinga.com logoUltragenyx Pharmaceutical Stock (NASDAQ:RARE) Earnings Dates and Earning Calls
benzinga.com - February 15 at 11:09 PM
msn.com logoUltragenyx Pharmaceutical GAAP EPS of -$1.52 beats by $0.10, revenue of $127.39M beats by $5.34M
msn.com - February 15 at 6:08 PM
benzinga.com logoRecap: Ultragenyx Pharmaceutical Q4 Earnings
benzinga.com - February 15 at 6:08 PM
markets.businessinsider.com logoUltragenyx Pharmaceutical Inc Q4 Loss decreases, beats estimates
markets.businessinsider.com - February 15 at 6:08 PM
finance.yahoo.com logoUltragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
finance.yahoo.com - February 15 at 6:08 PM
globenewswire.com logoUltragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
globenewswire.com - February 15 at 4:01 PM
marketbeat.com logoUltragenyx Pharmaceutical (NASDAQ:RARE) Given Overweight Rating at Cantor Fitzgerald
marketbeat.com - February 15 at 9:25 AM
benzinga.com logoPreview: Ultragenyx Pharmaceutical's Earnings
benzinga.com - February 14 at 3:41 PM
msn.com logoUltragenyx Pharmaceutical Q4 2023 Earnings Preview
msn.com - February 14 at 3:41 PM
marketbeat.com logoBarclays PLC Acquires 18,552 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
marketbeat.com - February 11 at 4:42 AM
marketbeat.com logoPier 88 Investment Partners LLC Lowers Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
marketbeat.com - February 9 at 4:26 PM
marketbeat.com logoUltragenyx Pharmaceutical (RARE) Scheduled to Post Quarterly Earnings on Thursday
marketbeat.com - February 9 at 12:11 PM
markets.businessinsider.com logoBuy Rating for Ultragenyx Pharmaceutical Amid Positive Gene Therapy Program Developments
markets.businessinsider.com - February 8 at 5:11 PM
finance.yahoo.com logoUltragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update
finance.yahoo.com - February 8 at 5:11 PM
markets.businessinsider.com logoBuy Rating for Ultragenyx Pharmaceutical Backed by Promising Gene Therapy Study Results and FDA Engagement
markets.businessinsider.com - February 7 at 9:08 PM
markets.businessinsider.com logoUltragenyx Pharmaceutical: Strong Buy on Promising Gene Therapy Trial Results and Regulatory Prospects
markets.businessinsider.com - February 7 at 11:07 AM
finance.yahoo.com logoUltragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA)
finance.yahoo.com - February 6 at 10:03 AM
marketwatch.com logoUltragenyx Gets EU Prime Medicine Designation For Neurogenetic Disorder Treatment
marketwatch.com - February 5 at 6:56 PM
marketbeat.com logoUltragenyx Pharmaceutical (NASDAQ:RARE) Shares Up 3.8%
marketbeat.com - February 5 at 3:42 PM
marketbeat.com logoGreat Lakes Advisors LLC Sells 14,216 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
marketbeat.com - February 5 at 6:30 AM
marketbeat.com logoFY2027 EPS Estimates for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Increased by Wedbush
marketbeat.com - January 31 at 7:50 AM
marketbeat.com logoUltragenyx Pharmaceutical (NASDAQ:RARE) PT Raised to $68.00 at Robert W. Baird
marketbeat.com - January 30 at 2:53 PM
marketbeat.com logoAssenagon Asset Management S.A. Lowers Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
marketbeat.com - January 30 at 5:59 AM
Get Ultragenyx Pharmaceutical News Delivered to You Automatically

Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter.



RARE Media Mentions By Week

RARE Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

RARE
News Sentiment

0.40

0.68

Average
Medical
News Sentiment

RARE News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

RARE Articles
This Week

18

4

RARE Articles
Average Week

Get Ultragenyx Pharmaceutical News Delivered to You Automatically

Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:RARE) was last updated on 2/29/2024 by MarketBeat.com Staff